Table: q1_q4_2019_prescription_drugs_wac_increases , manufacturer_name like C*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000137 Celgene 03/31/2019 59572063255 Apremilast 10 & 20 & 30 MG Tablet Therapy Pack 55 EA UU 01/03/2019 114.91 3398.00 05/29/2034 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Otezla were $1.275 billion.
Rx0000137 Celgene 03/31/2019 59572063106 Apremilast 30 MG Tablet 60 EA 01/03/2019 114.91 3398.00 05/29/2034 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Otezla were $1.275 billion.
Rx0000137 Celgene 03/31/2019 59572041000 Lenalidomide 10 MG Capsule 100 EA 01/03/2019 2434.17 71981.98 03/08/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137 Celgene 03/31/2019 59572041028 Lenalidomide 10 MG Capsule 28 EA 01/03/2019 681.57 20154.94 03/08/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137 Celgene 03/31/2019 59572041500 Lenalidomide 15 MG Capsule 100 EA 01/03/2019 2434.17 71981.98 03/08/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137 Celgene 03/31/2019 59572041521 Lenalidomide 15 MG Capsule 21 EA 01/03/2019 511.18 15116.23 03/08/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137 Celgene 03/31/2019 59572040200 Lenalidomide 2.5 MG Capsule 100 EA 01/03/2019 2434.17 71981.98 03/08/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137 Celgene 03/31/2019 59572040228 Lenalidomide 2.5 MG Capsule 28 EA 01/03/2019 681.57 20154.94 03/08/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137 Celgene 03/31/2019 59572042000 Lenalidomide 20 MG Capsule 100 EA 01/03/2019 2434.17 71981.98 03/08/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137 Celgene 03/31/2019 59572042021 Lenalidomide 20 MG Capsule 21 EA 01/03/2019 511.18 15116.23 03/08/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137 Celgene 03/31/2019 59572042500 Lenalidomide 25 MG Capsule 100 EA 01/03/2019 2434.17 71981.98 03/08/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137 Celgene 03/31/2019 59572042521 Lenalidomide 25 MG Capsule 21 EA 01/03/2019 511.18 15116.23 03/08/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137 Celgene 03/31/2019 59572040500 Lenalidomide 5 MG Capsule 100 EA 01/03/2019 2434.17 71981.98 03/08/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137 Celgene 03/31/2019 59572040528 Lenalidomide 5 MG Capsule 28 EA 01/03/2019 681.57 20154.94 03/08/2028 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Revlimid were $6.469 billion.
Rx0000137 Celgene 03/31/2019 68817013450 Paclitaxel Protein-Bound Particles 100 MG Suspension Reconstituted 1 EA UD 01/03/2019 46.60 1378.01 01/12/2034 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Abraxane was $663 million.
Rx0000137 Celgene 03/31/2019 59572050100 Pomalidomide 1 MG Capsule 100 EA 01/03/2019 2770.79 81936.32 06/21/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Pomalyst were $1.391 billion.
Rx0000137 Celgene 03/31/2019 59572050121 Pomalidomide 1 MG Capsule 21 EA 01/03/2019 581.87 17206.63 06/21/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Pomalyst were $1.391 billion.
Rx0000137 Celgene 03/31/2019 59572050200 Pomalidomide 2 MG Capsule 100 EA 01/03/2019 2770.79 81936.32 06/21/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Pomalyst were $1.391 billion.
Rx0000137 Celgene 03/31/2019 59572050221 Pomalidomide 2 MG Capsule 21 EA 01/03/2019 581.87 17206.63 06/21/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Pomalyst were $1.391 billion.
Rx0000137 Celgene 03/31/2019 59572050300 Pomalidomide 3 MG Capsule 100 EA 01/03/2019 2770.79 81936.32 06/21/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Pomalyst were $1.391 billion.
Rx0000137 Celgene 03/31/2019 59572050321 Pomalidomide 3 MG Capsule 21 EA 01/03/2019 581.87 17206.63 06/21/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Pomalyst were $1.391 billion.
Rx0000137 Celgene 03/31/2019 59572050400 Pomalidomide 4 MG Capsule 100 EA 01/03/2019 2770.79 81936.32 06/21/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Pomalyst were $1.391 billion.
Rx0000137 Celgene 03/31/2019 59572050421 Pomalidomide 4 MG Capsule 21 EA 01/03/2019 581.87 17206.63 06/21/2031 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information contained in this report is subject to the following limitations and assumptions: (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Celgene believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of September 27th, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. (3) Celgene did not acquire this product from another manufacturer within the previous five years. As a result, Celgene has left columns 14-22 blank because they are not applicable to this product. In 2018, total U.S. sales for Pomalyst were $1.391 billion.
Rx0000080 Cipla USA, Inc. 06/30/2019 69097080540 AZACITIDINE FOR INJ 100MG/VIAL 04/16/2019 105.00 210.00 None Non-innovator Multiple Source Drug 27696 None This product was not launched into the market until after the WAC change on 4/16/2020. Therefore, there was no product sold into the market at the old WAC. The WAC change was a result of further market analysis prior to launch. None There was no significant change or improvement to this drug None None None None None None None None None None None Not Acquired
Rx0000080 Cipla USA, Inc. 03/31/2019 69097086283 Calcium Acetate Tablet 03/04/2019 29.03 120.00 None Non-innovator Multiple Source Drug 9394000 None Increase in API Cost None Increase in API Cost None None None None None None None None None None https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=27 None
Rx0000146 Circassia Pharmaceuticals 09/30/2019 72124000202 Tudorza Pressair Inhalation Powder 400mcg 30 actuations 07/01/2019 84.12 260.00 03/13/2029 Single Source Drug None 1 None 1 None 1 06/17/2019 AstraZeneca 218840450 None The acquisition price amount entered reflects the price of a combination portfolio acquisition which includes future royalties based on estimated sales. 175.88 170.75 2015 140.70 None Circassia Pharmaceuticals acquired the rights to Tudorza Pressair from AstraZeneca effective 7/1/19. The WAC effective date reported by MediSpan (6/28/19) reflects the date Circassia listed the price of Tudorza to ensure Circassia met the quarterly administrative timeline updates that are performed by the pricing agencies. Circassia wanted to ensure that this information was available for the new NDC and new WAC effective, July 1st, however, Tudorza under the new NDC was not visible in wholesaler order systems nor available to customers for purchase until 7/1/19. Please let us know if you have additional questions regarding this issue. As previously stated, effective 7/1/19, Circassia Pharmaceuticals acquired Tudorza Pressair from AstraZeneca. Prior to 7/1/19, the NDC, owned by AstraZeneca, was 00310-0800-39. Beginning 7/1/19, the NDC, owned by Circassia, is 72124-0002-02.
Rx0000146 Circassia Pharmaceuticals 09/30/2019 72124000201 Tudorza Pressair Inhalation Powder 400mcg 60 actuations 07/01/2019 168.25 520.00 03/13/2029 Single Source Drug None 1 None 1 None 1 06/17/2019 AstraZeneca 218840450 None The acquisition price amount entered reflects the price of a combination portfolio acquisition which includes future royalties based on estimated sales. 351.75 341.51 2015 281.40 None Circassia Pharmaceuticals acquired the rights to Tudorza Pressair from AstraZeneca effective 7/1/19. The WAC effective date reported by MediSpan (6/28/19) reflects the date Circassia listed the price of Tudorza to ensure Circassia met the quarterly administrative timeline updates that are performed by the pricing agencies. Circassia wanted to ensure that this information was available for the new NDC and new WAC effective, July 1st, however, Tudorza under the new NDC was not visible in wholesaler order systems nor available to customers for purchase until 7/1/19. Please let us know if you have additional questions regarding this issue. As previously stated, effective 7/1/19, Circassia Pharmaceuticals acquired Tudorza Pressair from AstraZeneca. Prior to 7/1/19, the NDC, owned by AstraZeneca, was 00310-0800-60. Beginning 7/1/19, the NDC, owned by Circassia, is 72124-0002-01.
Rx0000320 CMP Pharma 12/31/2019 46287002004 CaroSpir spironolactone oral suspension 25mg/5ml 18ml 10/01/2019 26.50 320.80 10/28/2036 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000320 CMP Pharma 12/31/2019 46287002001 CaroSpir spironolactone oral suspension 25mg/5ml 473ml 10/01/2019 95.30 1154.80 10/28/2036 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000320 CMP Pharma 12/31/2019 46287000604 Sodium Polystyrene Suspension 120ml enema kit 11/01/2019 38.30 78.80 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000320 CMP Pharma 12/31/2019 46287000601 Sodium Polystyrene Suspension 473ml 11/01/2019 64.60 132.60 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000320 CMP Pharma 12/31/2019 46287000660 Sodium Polystyrene Suspension 60ml unit dose X 10 11/01/2019 85.40 175.40 None Non-innovator Multiple Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000200 Collegium Pharmaceuticals 03/31/2019 69865024502 NUCYNTA ER-100MG-100 TABLET 01/01/2019 75.26 760.20 09/22/2028 Single Source Drug None 1 We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. None None 1 None None None None None None None None None None None
Rx0000200 Collegium Pharmaceuticals 03/31/2019 69865025002 NUCYNTA ER-150MG-100 TABLET 01/01/2019 97.10 980.79 09/22/2028 Single Source Drug None 1 We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. None None 1 None None None None None None None None None None None
Rx0000200 Collegium Pharmaceuticals 03/31/2019 69865026002 NUCYNTA ER-200MG-100 TABLET 01/01/2019 123.26 1245.06 09/22/2028 Single Source Drug None 1 We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. None None 1 None None None None None None None None None None None
Rx0000200 Collegium Pharmaceuticals 03/31/2019 69865026501 NUCYNTA ER-250MG-100 TABLET 01/01/2019 154.21 1557.70 09/22/2028 Single Source Drug None 1 We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. None None 1 None None None None None None None None None None None
Rx0000200 Collegium Pharmaceuticals 03/31/2019 69865024002 NUCYNTA ER-50MG-100 TABLET 01/01/2019 40.69 411.05 09/22/2028 Single Source Drug None 1 We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. None None 1 None None None None None None None None None None None
Rx0000200 Collegium Pharmaceuticals 03/31/2019 69865023002 NUCYNTA IR-100MG-100 TABLET 01/01/2019 98.07 990.64 06/27/2025 Single Source Drug None 1 We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. None None 1 None None None None None None None None None None None
Rx0000200 Collegium Pharmaceuticals 03/31/2019 69865021002 NUCYNTA IR-50MG-100 TABLET 01/01/2019 62.98 636.15 06/27/2025 Single Source Drug None 1 We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. None None 1 None None None None None None None None None None None
Rx0000200 Collegium Pharmaceuticals 03/31/2019 69865022002 NUCYNTA IR-75MG-100 TABLET 01/01/2019 73.58 743.28 06/27/2025 Single Source Drug None 1 We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. None None 1 None None None None None None None None None None None
Rx0000200 Collegium Pharmaceuticals 03/31/2019 24510011510 XTAMPZA ER-13.5MG-100 CAPSULES 01/01/2019 59.09 655.98 09/02/2036 Single Source Drug None 1 We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. None None 1 None None None None None None None None None None None
Rx0000200 Collegium Pharmaceuticals 03/31/2019 24510012010 XTAMPZA ER-18MG-100 CAPSULES 01/01/2019 74.94 831.89 09/02/2036 Single Source Drug None 1 We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. None None 1 None None None None None None None None None None None
Rx0000200 Collegium Pharmaceuticals 03/31/2019 24510013010 XTAMPZA ER-27MG-100 CAPSULES 01/01/2019 104.25 1157.23 09/02/2036 Single Source Drug None 1 We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. None None 1 None None None None None None None None None None None
Rx0000200 Collegium Pharmaceuticals 03/31/2019 24510014010 XTAMPZA ER-36MG-100 CAPSULES 01/01/2019 128.31 1424.38 09/02/2036 Single Source Drug None 1 We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. None None 1 None None None None None None None None None None None
Rx0000200 Collegium Pharmaceuticals 03/31/2019 24510011010 XTAMPZA ER-9MG-100 CAPSULES 01/01/2019 40.15 445.70 09/02/2036 Single Source Drug None 1 We have never been profitable and have incurred net losses in each year since inception.  Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA in April 2016 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Substantially all of our net losses resulted from costs incurred from research and development programs to obtain and maintain regulatory approval for Xtampza ER, and from selling, general and administrative costs associated with our operations.  These factors, along with the increasing demands for rebates in order to provide improved access to patients, were considered in deciding to increase the wholesale acquisition cost of Xtampza ER. None None 1 None None None None None None None None None None None
Rx0000154 Corcept Therapeutics Incorporated 09/30/2019 76346007302 Korlym (mifepristone) 300mg Tablets 280-ct Bottles 08/01/2019 11480.00 139720.00 08/22/2038 Single Source Drug None 1 Corcept is committed to discovering, developing and making available to patients and physicians medicines that treat serious disorders for which there are few – or no – good treatment options. In setting Korlym’s price, we weigh (i) the increased cost of administrative and commercial activities, (ii) the increased cost of discovering and developing innovative new drug candidates and (iii) our commitment that no patient be denied Korlym for financial reasons. None N/A None None None None None None None None None None None WAC is reported at the package level. The information provided herein is provided to the best of our knowledge as of submission and based on our interpretation of applicable statutory and regulatory provisions. Information designated as confidential has been designated as such based on our understanding and belief that the subject information is non-public. Our provision of information shall not be interpreted as a waiver of any of our rights available under state, federal, or other applicable law with respect to the information contained herein or with respect to California SB 17, all of which we expressly reserve. Patent expiration dates do not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The drug was developed by Corcept.
Rx0000154 Corcept Therapeutics Incorporated 09/30/2019 76346007301 Korlym (mifepristone) 300mg Tablets 28-ct Bottles 08/01/2019 1148.00 13972.00 08/22/2038 Single Source Drug None 1 Corcept is committed to discovering, developing and making available to patients and physicians medicines that treat serious disorders for which there are few – or no – good treatment options. In setting Korlym’s price, we weigh (i) the increased cost of administrative and commercial activities, (ii) the increased cost of discovering and developing innovative new drug candidates and (iii) our commitment that no patient be denied Korlym for financial reasons. None N/A None None None None None None None None None None None WAC is reported at the package level. The information provided herein is provided to the best of our knowledge as of submission and based on our interpretation of applicable statutory and regulatory provisions. Information designated as confidential has been designated as such based on our understanding and belief that the subject information is non-public. Our provision of information shall not be interpreted as a waiver of any of our rights available under state, federal, or other applicable law with respect to the information contained herein or with respect to California SB 17, all of which we expressly reserve. Patent expiration dates do not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The drug was developed by Corcept.
Rx0000184 Cosette Pharmaceuticals, Inc. 12/31/2019 00713016612 MIGERGOT (Ergotamine Tartrate and Caffeine) Suppository, 2mg/100mg 11/04/2019 70.23 140.46 None Single Source Drug None 1 Operating primarily as a manufacturer of generic and over-the-counter drug products, Cosette Pharmaceuticals has a history of providing cost effective, high quality medications that help patients affected by various medical conditions. With that purpose in mind, Cosette carefully and holistically evaluates and weighs a variety of factors when pricing its medications, including: maintaining accessibility and affordability of its products for both patients and payors, market conditions, the overall increase in the cost of labor and goods, the required capital investment in manufacturing facilities and systems, and most importantly, the funding of research and new product development designed to meet the needs of patients and healthcare professionals today and in the future. It is critical to note that research and new product development is a high-risk endeavor, with significant costs being incurred on medications that eventually fail due to clinical, technical or commercial reasons. By considering all of these factors in pricing decisions, Cosette is taking the necessary steps to ensure the long-term availability of high quality prescription and over-the-counter drug products within its portfolio. None None 1 06/28/2019 Horizon Therapeutics PLC None 1 None 70.23 39.96 1983 0.01 None WAC of the Product when it was introduced in 1983 is unknown. Per recommendation of Rodney Garcia, while the WAC Five Year History recites Cosette's NDC number, it actually incorporates three separate NDC numbers from the following owners: Horizon, Crealta and G&W.
Rx0000181 Currax Pharmaceuticals LLC 12/31/2019 42847085009 Treximet 9 tab/pk (sumatriptan/naproxen) 85 mg/500 mg 10/25/2019 96.67 1062.90 04/02/2026 Single Source Drug None 1 None 1 None 1 04/30/2019 Pernix Pharmaceuticals 79600000 None The acquisition price reflects the total assets purchased out of bankruptcy - not the price limited to this single NDC. 967.23 880.09 2015 625.50 None Currax Pharmaceuticals LLC dba Cypress, Hawthorn and Macoven, acquired asset out of bankruptcy on April 30, 2019 from Pernix Pharmaceuticals. All pricing history prior to April 30, 2019 is not Currax Pharmaceuticals LLC's history. For the sake of clarity, Currax Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Currax Pharmaceuticals LLC maintains no liability for pricing and pricing history prior to April 30, 2019. Since the acquisition was in bankruptcy, the asset purchase amount for the product is not reported nor public.